Abstract. Forty mg TRH/day given orally for 3 weeks to 8 patients with mild primary hypothyroidism decreased serum TSH from a mean of 4.0 ng/ml \m=+-\1.2 (se) to 2.0 ng/ml \m=+-\0.4 (49%), and their mean incremental TSH response to iv TRH was equally reduced from 8.6 ng/ml \m=+-\2.5 to 4.0 ng/ml \ m=+-\1.9 (46%). In the same patients serum Prl was 8.2 ng/ml \m=+-\2.2 before oral TRH treatment and 6.6 ng/ml \m=+-\1.5 (81%) after treatment, and the mean incremetal Prl response to iv TRH was reduced from 43.5 ng/ml \ m=+-\5.0 to 35.9 ng/ml \m=+-\7 . 5 ( 8 3 %) . The oral administration of 10 mg of the dopamine antagonist metoclopramide increased mean serum TSH from 0.6 ng/ml \ m=+-\0.1 (se) to 0.7 ng/ml \ m=+-\0.1 (120%) in euthyroid subjects and from 4.0 ng/ml \m=+-\1.2to 5.7 ng/ml \m=+-\1.6 (145%) in patients with primary hypothyroidism, and mean serum Prl from 8.6 ng/ml \m=+-\0.8 to 109.5 ng/ml \m=+-\24.3 (1251%) and from 8.2 ng/ml \m=+-\2.2 to 119.6 ng/ml \ m=+-\45.5(1460%), respectively.
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The incremental TSH responses to iv TRH increased 2.3-fold in euthyroid subjects pre-treated with metoclopramide, while no change was observed in the TSH responsiveness in patients with primary hypothyroidism following metoclopramide pre-treatment. In the euthyroid subjects metoclopramide treatment had no effect on the Prl response to iv TRH. In the primary hypothyroid group metoclopramide pre-treatment caused a reduced Prl response to iv TRH in more than 50% of the patients. It is concluded that long-term TRH treatment decreased the serum levels of TSH and Prl as well as the incremental increases in TSH and Prl to iv TRH stimulation in patients with primary hypothyroidism. Long-term TRH treatment did not change the TSH and Prl responses to the dopamine antagonist metoclopramide.
Thyrotrophin (TSH) and prolactin (Prl) 
1979).
We have previously demonstrated the suppressive effect of long-term oral TRH administration on serum TSH as well as on the TSH response to iv TRH injection 
Results

T3 and T4
The hypothyroid subjects studied were under con¬ stant T4 medication during the study, and there was no significant difference between the results (mean ± SE) obtained before (T3 = 1.2 ± 0.1 nmol/1; T4 = 76.0 ± 3.0 nmol/1) they received oral TRH for 21 days and afterwards (T3 = 1.1 ± 0.1 nmol/1; T4 = 75.0 ± 9.0 nmol/1). In the euthyroid subjects the serum concentrations were: T3 = 1.2 ± 0.1 nmol/1 and T4 = 103.0 ± 6.8 nmol/1).
TSH
The results of the TSH determinations in the euthyroid patients and in the hypothyroid control subjects are illustrated in Fig. 1 .
Mean serum TSH levels were 0.6 ng/ml ±0.1 (SE) in the control subjects, and increased to 0.7 ng/ml ± 0.1 (119%) 2 h after oral administration of 10 mg of the dopamine antagonist metoclopramide.
In the primary hypothyroid patients mean basal serum TSH was 4.0 ng/ml ±1.2 before and 5.7 ng/ml ± 1.6 (145%) 2 h after metoclopramide. In the control group treatment with the dopaminereceptor blocking agent caused an increase in serum TSH in 5 of the 9 control subjects, while serum TSH levels were unchanged in 3 subjects and showed a small decline in one subject. In the primary hypothyroid group, metoclopramide treatment increased serum TSH levels in 7 of the 8 patients, while in the 8th patient a decline in serum TSH was observed.
The TSH response to iv TRH, expressed as mean Amax TSH (see Materials and Methods), was 0.4 ng/ml ±0.1 before and 1.0 ng/ml ± 0.2 2 h following metoclopramide in the control subjects. All control subjects responded to TRH with an increase in serum TSH and the increments were higher after metoclopramide (P<0.01) than be¬ fore. In the hypothyroid group mean Amax TSH after iv TRH amounted to 8.6 ng/ml ± 2.5, as compared to 7.2 ng/ml ± 1.7 when metoclopra¬ mide was given 2 h before iv bolus of TRH. The difference between the mean increments in serum TSH is statistically not significant.
Treatment of the 8 primary hypothyroid patients with 40 mg TRH orally for 21 days caused a significant (P < 0.05) reduction in serum TSH from 4.0 ng/ml ± 1.2 before TRH to 2.0 ng/ml ± 0.4 (49%) at the end of the TRH treatment period. Administration of metoclopramide to these pa¬ tients, at the end of the TRH treatment period, had no significant effect on serum TSH (2.4 ng/ml ± 0.6(125%).
The TSH response to iv TRH, expressed as mean Amax TSH, was 4.0 ng/ml ± 1.9 (46%) after the treatment with oral TRH as compared to 8.6 ng/ml ± 2.5 before the treatment. This reduction is, however, statistically insignificant because an increased response was observed in one patient (S.A.). All other patients showed substantial de- (Fig. 2) . The statistical evaluation gives the same result whether or not patient A. L. is included (vide supra).
Discussion
As previously demonstrated (Caron et al. 1978) and cattle (Calabro 8c MacLeod 1978) , and dopamine inhibits both TSH and Prl secretion in isolated rat pituitary cells (Foord et al. 1980; Caron et al. 1978 
